Cover Image

Induction of HIV from latency by a novel molecule

Saved in:

Bibliographic Details
Main Authors:	N.M. Archin (Author), D. Boden (Author), J. Kirchherr (Author), B. Allard (Author), K. Sholtis (Author), J.D. Kuruc (Author), G. Kraus (Author), D.M. Margolis (Author)
Format:	Book
Published:	Elsevier, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
by: C. Gay, et al.
Published: (2019)

PP 1.4 - 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency
by: T.L. Simermeyer, et al.
Published: (2022)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Single cell analysis of HIV latency reveals diverse proviral and host cell behaviour
by: E.P. Browne, et al.
Published: (2017)

SMAC mimetics reverse HIV latency by selective activation of the non-canonical NF-κB pathway
by: G.C. Sampey, et al.
Published: (2017)

PP 1.24 - 00132 BET PROTACS Reveal BRD4 Disruption of the 7SK/P-TEFb Equilibrium is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells
by: A-M. Turner, et al.
Published: (2022)

Epigenomic characterisation of a primary cell model of HIV latency
by: E. Browne, et al.
Published: (2019)

Targeted screens identify new chromatin regulators of HIV latency
by: A.-M. Turner, et al.
Published: (2017)

A modified viral outgrowth assay incorporating ultra-sensitive P24 measurements
by: N. Archin, et al.
Published: (2017)

Defining the landscape of HIV-specific T-cell responses in HIV-1 infected durably suppressed participants
by: J. Warren, et al.
Published: (2017)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)

The steroid receptor coactivators are targets for reactivation of HIV latency
by: B.C. Nikolai, et al.
Published: (2015)

PP 3.10 - 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment
by: C. Lewis, et al.
Published: (2022)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

Evaluation of IAP/SMAC mimetics as latency reversal agents in primary cells and cytokine induction in in vivo models predictive of cytokine release
by: B. Howell, et al.
Published: (2019)

HIV-1 in the latent reservoir is largely sensitive to circulating T cells
by: J. Warren, et al.
Published: (2019)

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency
by: B.J. Howell, et al.
Published: (2015)

Triazol-1-ol analogues as novel therapeutic leads towards reactivating and eradicating latent HIV-1 by manipulating SUMOylation of STAT5
by: A. Bosque, et al.
Published: (2015)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

OP 1.7 - 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir
by: M. Pardons, et al.
Published: (2022)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Adoptive T cell as a strategy for targeted delivery of immune checkpoint therapy
by: J. Sung, et al.
Published: (2017)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

Shining the RNA-Seq microscope on models of HIV latency
by: C.H. Woelk, et al.
Published: (2015)

OP 1.4 - 00053 Definitive evidence of a persistent HIV reservoir in human brain myeloid cells despite ART
by: Y. Tang, et al.
Published: (2022)

CD8 T cells from HIV positive individuals on ART have a skewed differentiation phenotype and impaired proliferative responses
by: G. Clutton, et al.
Published: (2017)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

Sustained HIV release by single persisting CD4+ T cells during latency disruption
by: J.M. Hataye, et al.
Published: (2015)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells.
by: J. Jacobson, et al.
Published: (2017)

Human endogenous retrovirus expression landscape in models of HIV-1 latency
by: M. de Mulder Rougvie, et al.
Published: (2019)

13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption
by: W.S. Lee, et al.
Published: (2017)

A novel, ultra-sensitive technology for quantifying the HIV unintegrated linear DNA responsible for pre-integrative latency
by: J. Dutrieux, et al.
Published: (2019)

A novel, ultra-sensitive technology for quantifying the HIV unintegrated linear DNA responsible for pre-integrative latency
by: J. Dutrieux, et al.
Published: (2019)

Estrogen potently blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs and novel cure strategies
by: J. Karn, et al.
Published: (2015)

Galectin-1 promotes HIV-1 latency reactivation
by: J. Rubione, et al.
Published: (2019)